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Background: Several previous studies have shown relationships between adherence to HIV antiretroviral therapy
(ART) and the viral load, the CD4 cell count, or mortality. However, the impact of variability in adherence to ART on
the immunovirological response does not seem to have been investigated yet.
Methods: Monthly adherence data (November 1999 to April 2009) from 317 HIV-1 infected patients enrolled in
the Senegalese ART initiative were analyzed. Latent-class trajectory models were used to build typical trajectories
for the average adherence and the standardized variance of adherence. The relationship between the standardized
variance of adherence and each of the change in CD4 cell count, the change in viral load, and mortality were
investigated using, respectively, a mixed linear regression, a mixed logistic regression, and a Cox model with
time-dependent covariates. All the models were adjusted on the average adherence.
Results: Three latent trajectories for the average adherence and three for the standardized variance of adherence
were identified. The increase in CD4 cell count and the increase in the percentage of undetectable viral loads were
negatively associated with the standardized variance of adherence but positively associated with the average
adherence. The risk of death decreased significantly with the increase in the average adherence but increased
significantly with the increase of the standardized variance of adherence.
Conclusions: The impacts of the level and the variability of adherence on the immunovirological response and
survival justify the inclusion of these aspects into the process of patient education: adherence should be both high
and constant.
Keywords: Latent trajectory modeling, Classification, Patient adherence, Highly active antiretroviral therapyBackground
Two decades ago, the advent of highly active antiretro-
viral therapy (HAART) has improved the health status
of many people living with HIV and has significantly
reduced HIV-linked death rates [1,2]. To date, several
studies have shown the relationships between adherence
to HAART and each of: plasma viral load, CD4 recovery,
the progression toward AIDS, or mortality [3-8]: however,* Correspondence: olayideb@yahoo.fr
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unless otherwise stated.the impact of the variability in adherence to HAART on
the immunovirological response does not seem to have
been studied yet.
For various reasons, unlike the case in high-income
countries, the rate of access to HAART in most Sub-
Saharan African countries has long been low [9,10]: less
than 4% [9]. However, great efforts have been recently
made to improve that access. Senegal was one of the first
Sub-Saharan African countries to initiate a policy of
universal access to HAART. Indeed, the Initiative Sénéga-
laise d’Accès aux Antirétroviraux (ISAARV) was launched
in 1998 [11]. Not long after, an operational research pro-
ject was designed to follow-up the patients, evaluate the
level of adherence to HAART, and find the reasons ofl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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have been the object of several studies over various time
periods. These studies have analyzed the determinants of
adherence, the levels of adherence, and the link between
the level of adherence and the immunovirological re-
sponse or mortality [13-15].
The present work examines, first, not only the level of
adherence to HAART (i.e., the average adherence) but
also the variability of adherence over time. It examines
then the impact of this variability on the viral load, the
CD4 cell count, and mortality with adjustment on the
average adherence.
Methods
The data source
The original dataset is that of the ANRS 1215 cohort.
This cohort included 404 patients with HIV-1 infection
receiving HAART within the context of ISAARV [12,16].
These patients were included between August 1998 and
April 2002. The detailed inclusion criteria may be found
in previous studies on the ISAARV cohort [12,15,16]. In
short, 80 patients were enrolled between January 2000
and April 2001 if they were HAART-naive and had a CD4
cell count < 350 cells/mL and a plasma viral load > 3×104
copies/mL. The 324 others were enrolled between August
1998 and April 2002 if they had < 350 CD4 cells/mL (<200
CD4/mL after October 2000) and a plasma viral load > 105
copies/mL (asymptomatic patients) or > 104 copies/mL
(paucisymptomatic patients); symptomatic patients free
from major opportunistic infections were included what-
ever the CD4 cell count or the plasma viral load.
The investigation regarding the adherence to HAART
started on November 1999 for the first 180 patients en-
rolled in ISAARV and on May 2004 for the 224 others.
At first, adherence-related data were reported for 330
patients (the others died before data collection). How-
ever, later, the data of 13 patients were found irregular
and unsuitable for analysis. The final analysis concerned
thus 317 patients: 175 women and 142 men. The mean
age was 37.5 years (interquartile range (IQR): 31–43
years). The time on HAART was censored at 108 months.
The median time on HAART was 92 months (IQR: 84–
105 months).
The patients were first seen two weeks, one month,
and two months after HAART initiation; then at least
every two months. They had to obtain the drugs from a
single centre (Fann Hospital, Dakar). At each drug deliv-
ery, the pharmacist estimated adherence by counting the
number of remaining pills and by interviewing the pa-
tients about the reasons for non-adherence. The adher-
ence to each drug was calculated as the number of pills
taken divided by the number of pills prescribed over the
last month. The overall adherence over the last 30 days
was the arithmetic mean of the distinct drug adherences.Besides, every six months, each patient had laboratory
investigations that included plasma HIV viral load and
CD4 cell count. The detailed investigations can be found
in a previous publication [16].
Ethics
The study was conducted with the approval of the Senegal-
ese Ministry of Health (Conseil National de la Recherche
en Santé No. 0017 MSP/DS/CNRS and Direction de la
Santé No. 0760 MSP/DS/CNRS). All the patients gave writ-
ten informed consents for participation in the study.
Statistical analyses
All data were censored at death or last visit before the
end of the 108th month after HAART initiation.
Starting from the 12th month, a monthly moving aver-
age and a monthly moving variance of adherence to
HAART were calculated using, at each new monthly time
point, the adherence over the previous twelve months.
These two values are highly linked: a high average adher-
ence is usually associated with a low variance of adher-
ence; thus, they carry the same information concerning
the impact of adherence on the immunovirological re-
sponse. A measure of variance that is independent of the
average was thus necessary. This measure was designed as
follows. The averages of adherence were first sorted by in-
creasing order then grouped into 604 small-amplitude
classes of nearly 30 averages. The corresponding variances
were sorted in increasing order within each class and
assigned a rank. The empirical repartition function of the
variances within each class of averages was obtained by
dividing the ranks of the ordered variances by 1 + the class
size. The quantiles of this empirical repartition function
were then assimilated to the quantiles of a normal distri-
bution. This provided standardized variances of adherence
to HAART.
A latent-class trajectory model was used to distinguish
typical trajectories [17-19] of the moving averages of ad-
herence to HAART. In this model, in accordance with
previous analyses by Bastard et al. [15], the number of
latent-classes was fixed to three, which is sufficient to
show the trends without increasing the complexity of the
model. This model considered time as a random effect
and a random intercept for “patient”.
To model the change in the moving average over time,
several functions were considered but, to estimate the
model parameters, the adopted model was the one that
fitted the best the moving averages without presenting
algorithm convergence problems. This model considers
time t (in months) as covariate and a function of time hT
(t) that allows for several inflexion points. It can be writ-
ten as follows.
Let ŷit be the average adherence predicted for patient i
for month t since HAART initiation. For T ∈ {12, 24,
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hT tð Þ ¼ t−T when t > T0 otherwise

. Thus, y^it ¼
XJ
j¼1
pij  f j tð Þ
h i
with pij as the posterior probability for patient i to belong
to group j and f j tð Þ ¼ β0j þ β1j  t þ
X
T
βTj  hT tð Þ
h i
as
the mean of a Gaussian distribution conditionally on the
fact that i belongs to group j. The value attributable to
typical trajectory j at month t is thus the mean of f j(t)
weighted by pij values.
A typical trajectory of average adherence was attrib-
uted to each patient according to the maximum a pos-
teriori probability (MAP) rule [19]. The same model was
also applied to the standardized variances of adherence
to obtain, first, typical trajectories of variance in adher-
ence, then a classification of the patients according to
these typical trajectories.
To investigate the link between adherence to HAART
and the viral load, percentages of patients with undetect-
able viral loads (<1000 copies/mL of blood) were calculated
per six-month periods, for each average-standardized vari-
ance pair. The link between these percentages and adher-
ence was explored using a mixed logistic regression that
considered the classes of adherence averages and the stan-
dardized variances as well as their interactions as fixed ef-
fects and the six-month period as random intercept.
To investigate the link between adherence to HAART
and the CD4 cell count, a six-month rate of change (in-
crease or decrease) in CD4 cell count was calculated for
each average-standardized variance pair. These rates of
change were transformed into monthly values by dividing
by 6. The link between the latter values and adherence
was explored using a mixed linear model that included
the classes of adherence averages and the standardized
variances as well as their interactions as fixed effects and
“six-month” as random intercept.
To investigate the link between adherence to HAART
and mortality, the values of the moving averages and
standardized variances of adherence were considered as
explanatory variables in a time-dependent Cox model
[20-22]. The change in patient adherence (i.e., the mean
and the standardized variance) was not considered con-
stant over time.
All statistical analyses were performed using packages
from R (version 3.0.2) software [23].
Results
Adherence trajectories
The left panel of Figure 1 shows the three typical trajec-
tories of the average adherence to HAART: i) one trajec-
tory of “constantly high” (cH) average that groups 69.47%
of the moving averages and whose average is close to 95%;
ii) another trajectory of “high but slowly decreasing”(HsD) average (before a sharp increase over the last year)
that groups 17.36% of the moving averages and whose
average ranges from 90% (up to the fourth year) to 65%
(on the seventh and eighth year); iii) a third trajectory of
“decreasing then rapidly increasing” (DrI) average that
groups the remaining 13.17% of the moving averages and
whose average falls sharply from 80% over the first year to
less than 50% on the third year before increasing up to
90% over the seventh and eighth year. Regarding the sec-
ond trajectory, the sample size was not large and most of
the deaths within this group (12 among 54 persons of this
group) occurred before the last year. Hence, the patients
still alive in this group were those who had best improved
their adherence during the very last year, which explains
the sharp increase of adherence during the last year.
The right panel of Figure 1 shows the three typical tra-
jectories of the standardized variance of adherence to
HAART. Though irregular along time, these trajectories
are somewhat ordered. They may be labelled “low” (group-
ing 22.59% of the moving variances), “moderate” (grouping
49.08% of moving variances) and “high” (grouping 28.32%
of the moving variances).
Table 1 shows the distribution of the 317 patients in
the nine average-standardized variance groups according
to the MAP rule. About 98% and 90% of the MAPs were
higher than 0.85 regarding, respectively, the average ad-
herence latent trajectories and the standardized variance
in adherence latent trajectories.
Among the 221 patients with cH average adherence,
nearly six out of ten patients had a moderate standard-
ized variance. The distributions of HsD and DrI subjects
over the standardized variance of adherence groups were
obviously more uniform than that of cH. The distribu-
tions of the patients in the different groups of average
adherence or standardized variance of adherence had no
significant links with some patient baseline characteris-
tics (at initiation of HAART) such as sex, stage of HIV
infection, or age (see Additional file 1 for details).
Impact of the variability in adherence to HAART on the
viral load
Panel a of Figure 2 shows the mean percentages of
undetectable viral loads according to the nine average/
standardized variance groups. The calculation of these
means did not include the percentages found at HAART
initiation which were nearly 0 in all groups. The mean
percentage increased together with the average adher-
ence. The significance of this association was confirmed
by the results of the mixed logistic regression. Table 2
shows clearly that the probability of undetectable viral
load increased when the status shifted from DrI average
adherence to HsD average adhrence (OR = 2.88; 95% CI:
1.52–5.45) or to cH average adherence (OR = 2.91; 95%
CI: 1.74–4.86).
Figure 1 Trajectories of adherence averages (left panel) and standardized variances (right panel).
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association between the mean percentage of undetect-
able viral load and the standardized variance in adher-
ence. However, this association had not the same effect
size within each of the three groups, which means that
there was a significant interaction between the average
adherence group and the standardized variance group.
Indeed, in the group of cH average adherence, the odds
of the viral load increased by 76% (OR = 1.76; 95% CI:
1.35–2.30) when the status shifted from “High” to “Mod-
erate” variance and by 82% (OR = 1.82; 95% CI: 1.25–2.66)
when the status shifted from “High” to “Low” variance
(Table 2, bottom rows). In the group of DrI average adher-
ence, though not significant, the associations between the
standardized variance of adherence to HAART and viral
load detectability showed the same trend as in the group
of cH average adherence (Moderate vs. High variance:
OR = 1.28; 95% CI: 0.64–2.58 and Low vs. High vari-
ance: OR = 1.73; 95% CI: 0.75–4.00). In the group of
HsD average adherence, the associations between the
standardized variance of adherence to HAART and viralTable 1 Distributions of the patients according to the classes
HAART
Averag
Variance classes cH H
Low 40 18.10% 20
56.34% 28.17%
Moderate 127 57.47% 14
81.94% 9.03%
High 54 24.43% 20
59.34% 21.98%
Total 221 (69.72%) 54 (17.03%)
Bold numbers are the numbers of patients in the nine average-standardized varian
Column percentages are below each number. cH: constantly high average adheren
rapidly increasing average adherence.load detectability showed an opposite trend (though not
significant) to that of the other two groups of average
adherence (Moderate vs. high variance: OR = 0.69; 95%
CI: 0.37–1.28 and Low vs. High variance: OR = 1.71;
95% CI: 0.85–3.45).
Impact of the variability in adherence to HAART on the
CD4 cell count
Panel b of Figure 2 shows the distributions of the rates of
change (increase or decrease) of the CD4 cell count ac-
cording to the nine average/standardized variance groups.
Within the groups of cH and HsD average adherence,
more than 75% of the rates were positive; i.e., were in-
creasing. Within the group DrI average adherence, the
IQRs of the rates include negative values (i.e., decreasing
rates). In other words, the higher was average adherence,
the higher was the rate of change of the CD4 cell count,
which means that the higher was the average adherence,
the faster was the immunologic recovery.
Besides, panel b of Figure 2 shows that, in any given
average adherence group, the rate of change of the CD4of average and standardized variance of adherence to
e classes
sD DrI Total
37.04% 11 26.19% 71 (22.4%)
15.49%
25.92% 14 33.33% 155 (48.9%)
9.03%
37.04% 17 40.48% 91 (28.70%)
18.68%
42 (13.25%) 317 (100%)
ce classes of adherence. The row percentages are at the right of each number.
ce - HsD: high but slowly decreasing average adherence - DrI: decreasing then
Figure 2 Distributions of undetectable viral loads and CD4 cell counts according to average adherence and standardized variance
of adherence groups. Panel a: Mean percentages of undetectable viral loads (with their 95% CIs) starting from the 6th month after HAART
initiation. Panel b: Variations, by six-month intervals, of the CD4 cell counts starting from the 6th month after HAART initiation. cH: constantly
high average adherence - HsD: high but slowly decreasing average adherence - DrI: decreasing then rapidly increasing average adherence.
Table 2 Relationships between adherence (average and
standardized variance) and the viral load according to
the mixed logistic regression
Adherence groups Odds ratio* 95% CI
Reference group† 1 -
Moderate variance 1.28 0.64 - 2.58
Low variance 1.73 0.75 - 4.00
HsD average adherence 2.88 1.52 - 5.45
Moderate variance 0.69 0.37 - 1.28
Low variance 1.71 0.85 - 3.45
cH average adherence 2.91 1.74 - 4.86
Moderate variance 1.76 1.35 - 2.30
Low variance 1.82 1.25 - 2.66
*Corresponds to a six-month period. † Corresponds to the case of DrI average
and High variance. DrI: decreasing then rapidly increasing average adherence -
HsD: high but slowly decreasing average adherence - cH: constantly high
average adherence.
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standardized variance of adherence to HAART. This trend
was very clear in group DrI average, which could mean
that the higher was the standardized variance of adher-
ence, the slower was the immunologic recovery.
Table 3 shows the results of the mixed linear model re-
garding the trends of the monthly CD4 cell count. This
trend remained positive on average whatever the average-
standardized variance pair, which means an overall in-
crease of the monthly mean of CD4 cell count. This
increase was significantly more important when the status
shifted from DrI average to cH average than when it
shifted to HsD average (the differences being 4.70 and
4.28 CD4 cells/mm3 per month, respectively). There was
still a significant relationship between the increase in the
monthly mean CD4 cell count and the standardized vari-
ance of adherence after adjustment on the average adher-
ence to HAART. Indeed, within the group DrI average,
the monthly cell count increased significantly when the
standardized variance decreased: the difference was 2.79
CD4 cells/mm3 per month when the status shifted from
Table 3 Relationships between adherence (average and
standardized variance) and the CD4 cell count according
to the mixed linear model
Adherence groups Monthly change in CD4 cell
count (cells/mm3 blood)
95% CI
Reference group* 0.04 −0.93 - 1.01
Moderate variance 2.43 1.20 - 3.66
Low variance 2.79 1.24 - 4.34
HsD average adherence 4.28 3.22 - 5.35
Moderate variance −0.41 −1.44 - 0.63
Low variance 2.20 1.20 - 3.21
cH average adherence 4.70 3.82 - 5.58
Moderate variance −0.33 −0.70 - 0.05
Low variance 0.76 0.26 - 1.25
*Corresponds to the case of DrI average (decreasing then rapidly increasing
average adherence) and “High” variance. All the other values correspond to
the deviation from this baseline. HsD: high but slowly decreasing average
adherence - cH: constantly high average adherence.
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“High” to “Moderate” variance.
Within the group HsD average, the monthly mean of
CD4 cell count did not seem to change within High and
Moderate variance; however, it was significantly higher
in the High than in the Low variance group (Difference:
2.20; 95% CI: 1.20–3.21 CD4 cells/mm3 per month).
Similarly, within the group cH average, there seemed
to be no significant difference between the increases
in the monthly mean of the CD4 cell count in High
and Moderate variance. This increase was significantly
more important in the Low than in the High variance
group (Difference: 0.76; 95% CI: 0.26–1.25 CD4 cells/mm3
per month).
Impact of the variability in adherence to HAART on
mortality
Over the whole follow-up period, the moving average of
adherence ranged from 0.91 to 99.97 (IQR: 87.30–98.41)
whereas the moving standardized variance ranged from
−1.85 to 1.85 (IQR: −0.55–0.51). The total number of
deaths over the follow-up period was 52 (16.40% of the
participants).
The results of the Cox model showed that the instant-
aneous risk of death was significantly associated with
both the average and the standardized variance of adher-
ence to HAART.
In the univariate analysis, i) a 10% increase in the aver-
age adherence induced a 30% decrease of the relative
risk of death (HR = 0.73; 95% CI: 0.66–0.81); and, ii) a
unit increase in the standardized variance induced a 50%
increase in the relative risk of death (HR = 1.49; 95% CI:
1.04–2.12).
In the multivariate analysis, all things being equal, i) a
10% increase in the overall adherence induced a 30%decrease of the relative risk of death (HR = 0.73; 95% CI:
0.66–0.81); and, ii) a unit increase in the standardized
variance induced a 45% increase in the relative risk of
death (HR = 1.45; 95% CI: 1.03–2.06).
In the multivariate analysis, a model that included a
term of interaction between the average and the stan-
dardized variance of adherence did not show a better fit
than a model without this interaction. However, it helped
showing that the higher was the average adherence, the
higher was the effect of the standardized variance on the
risk of death.
Discussion
The ANRS 1215 cohort provided the advantage of a long
follow-up of patients with HIV receiving HAART; this
allowed the use of latent-class trajectories for the aver-
age and the variance of adherence to HAART over time.
The study was able to establish associations between ad-
herence (through its average or variance) with the viral
load, the CD4 cell count, and mortality. The present
study showed that cH was the dominant trajectory. This
may be explained by a bias of longer patient survival but
also, past the first year of treatment, by the ongoing
advances in HAART (better tolerance, less pills to be
taken, fixed-dose combinations, and once-a-day pill).
A few previous studies have already used trajectory
groups of average adherence to HAART [15,24]. Here,
the study goes beyond the simple average and identifies
independently trajectory groups of variance of adherence
within each average adherence group.
The present results are in agreement with others regard-
ing the impact of the level of adherence to HAART on the
immunovirological response or on mortality. Indeed, part
of the present results confirm those of Haubrich et al. [4]
and of Mannheimer et al. [6] regarding the increase in the
percentage of undetectable viral load (meaning viral dis-
appearance from blood) and the increase in the CD4 cell
count together with the increase in the average adherence.
Another part of the present results confirm those of
Palella et al. [3], Nachega et al. [7], and Abaasa et al. [8] re-
garding the link between the average adherence and pa-
tient survival. Moreover, in a recent study conducted in
Burkina Faso [25], the authors expressed adherence with a
score (ranging from 0 to 10 points) and considered it in a
Cox model as a time-varying covariate to point out that
the less adherent patients had a higher risk of death. By
classifying adherence into two categories (optimal: 8–10
points and sub-optimal: 0–7 points), the authors showed
also that patients with optimal adherence had the best
CD4-cell-count recovery.
Nevertheless, the results reported here present real nov-
elties regarding the impact of the variance in adherence to
HAART on the immunovirological response and on sur-
vival. Indeed, whatever the level of the average adherence:
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increased; ii) the probability of achieving an undetect-
able viral load increased when the variance was low;
and, iii) the risk of death increased along with the in-
crease of the variance.
Various methods have been used to measure adher-
ence [26-28] and each has its own advantages and limits.
The present study shows one approach of dissociating
the average adherence from the variance of adherence. A
Moving average and variance over 12-month blocks of
time was used because the viral load and the CD4 cell
count at a given time point are deemed less dependent
on current than on past adherence. Besides, the classic
average adherence showed high frequencies circa 50%
but low frequencies circa 0% and 100%. A transformation
of the variance was thus necessary to dissociate the infor-
mation it provides from that provided by the mean. A
standardized measurement of the variance keeps the vari-
ances within the same order of magnitude whatever the
means. This method provides a more efficient measure-
ment of the variability in adherence that is independent of
the average adherence and allows focusing on the impacts
of the variance that are not repeats of the impacts of the
mean. However, though this method allowed showing sig-
nificant impacts of adherence variability on some elements
of the immunovirological response, the interpretation of
the size effects remained difficult.
The latent-class trajectory approach with the average
and the variance of adherence offers the advantage of
showing that the effects of the variance may change ac-
cording to the level of the average and avoids enforcing
a specific form to the link between average and variance.
However, this approach may induce some loss of power
regarding the significance of the effects.
Conclusions
There are significant relationships between the variance
of the adherence to HIV antiretroviral therapy and the
viral load, the CD4 cell count, and mortality. The impacts
of the two components (level and variability) of adherence
on the immunovirological response and survival justify
the inclusion of these aspects into the process of patient
education: adherence should be both high and constant; a
high but irregular adherence is not favourable to an effi-
cient HAART.
Additional file
Additional file 1: Relationship between the distributions of the
patients in the different groups of average adherence or
standardized variance of adherence and some patient baseline
characteristics.
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